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Introduction 
Catheter ablation to isolate pulmonary veins (PVs) is an effective 
treatment for drug-refractory paroxysmal atrial fibrillation (PAF)[1,2]. 
PV isolation is conventionally achieved using radiofrequency (RF) en-
ergy to create contiguous and transmural point-to-point lesions encir-
cling the veins[1]. This is however time consuming, technically challeng-
ing and PV reconnection causing AF recurrence remains a problem[2,3].
A balloon-based approach using cryothermal energy has emerged 
as a comparable alternative with the potential of isolating PVs with 
a ‘single-shot’ technique and associated with lower risk of thermal 
injury and PV stenosis compared to radiofrequency (RF) energy 
sources[4]. A recent systematic review has suggested good acute 
procedural safety and efficacy with a one year freedom from AF 
of 73%[5]. Our own randomised control trial (The Cryo Versus RF 
Trial) comparing segmental ostial isolation with cryoballoon to wide 
antral circumferential ablation (WACA) of PVs using RF energy 
and a novel approach combining both found that cryoballoon and 
the combined approach were both superior to the conventional RF 
approach at 1 year. There was no significant difference between using 
cryoballoon alone compared to the combined approach [6].
  However, long term prospective data comparing the efficacy of 
cryoballoon and RF ablation is lacking. Furthermore, there are little 
data comparing ablation strategies with respect to the extent and 
pattern of PV reconnection. In this study, we sought to address this 
by following up the cohort of patient in  The Cryo Versus RF trial, 
looking at the long-term outcome following ablation and studying 




  234 patients undergoing first-time catheter ablation of PAF 
www.jafib.com Oct-Nov 2018| Volume 11| Issue 3 
Abstract
 Introduction:Long term prospective data comparing the efficacy of radiofrequency (RF) and cryoballoon ablation (CRYO) for paroxysmal 
atrial fibrillation (PAF) is lacking. We report the long-term outcomes of a randomized control trial comparing CRYO to RF ablation, or a novel 
COMBINED approach (RF followed by CRYO) for PAF. We studied the number and pattern of pulmonary vein (PV) reconnections in patients 
undergoing repeat procedure(s). The COMBINED approach had significantly higher single procedure success rate and is associated with the 
fewest reconnected PVs.
Methods: 203 patients who underwent first time PAF ablation in a randomized clinical trial comparing CRYO (67), RF (67) and COMBINED 
(69) approaches were followed up. All patients with symptomatic recurrence of AF were offered a repeat procedure(s). Reconnected PV(s) at 
repeat procedure(s) were recorded. In a subset, the PV reconnection sites during the first repeat procedure were prospectively assessed and 
categorised into one of 8 segments. 
Results: At 5 years, 57% of COMBINED patients remained free of AF after a single procedure compared to 47% CRYO and 19% RF patients 
(p<0.001 COMBINED vs RF and CRYO vs RF, p=0.043 COMBINED vs CRYO). During the first repeat procedure, the COMBINED group had less 
number of reconnected PVs (mean number of reconnected PVs in the COMBINED group 1.2 vs 2.3 CRYO and 2.4 RF, p=0.034). There was a 
different pattern of PV reconnection comparing the CRYO and RF groups.
Conclusion:The COMBINED approach had a significantly higher single procedure success rate with fewer reconnected PVs and fewer 
reconnection sites compared to either CRYO or RF alone. CRYO in turn was superior to RF. PV reconnection pattern differed between CRYO 
and RF and the synergistic effect of the COMBINED approach may explain the improved single procedure efficacy.
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were randomized to cryoballoon (CRYO, n=78), radiofrequency (RF, 
n=77), or a novel cryoballoon and radiofrequency combined procedure 
(COMBINED, n=79) at a single institution as part of a randomized 
controlled trial ( The CryoVs RFA trial), the results of which have 
been reported[6]. The study was approved by the local research ethics 
committee and was prospectively registered on NIH clinical trials. 
gov (NCT01038115). All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or comparable 
ethical standards.
 Briefly, patients enrolled were aged over 18 years, had documented 
paroxysmal AF on at least two occasions and accepted for catheter 
ablation for AF. Patients were excluded from the trial if they had 
severe left atrial dilatation (greater than 50mm in diameter), severe 
valvular disease, or previous left atrial ablation.
Catheter ablation procedures
  All patients underwent trans-oesophageal echocardiography 
pre-procedure and were anticoagulated without interruption. The 
procedures were performed under local anaesthetic (lidocaine), and 
conscious sedation (midazolam and diamorphine). A quadripolar 
catheter was inserted into the coronary sinus and a multipolar 
circular mapping catheter was used for mapping of the PVs. Double 
transseptal puncture was performed when dual transseptal access was 
required.
 For CRYO, a 28mm and/or a 23mm first generation Arctic Front 
cryoballoons (Medtronic, Minneapolis, MN, USA) used. Retrograde 
PV angiography was used to demonstrate occlusion. Two freezes of 
up to 300s were performed initially in each PV with phrenic nerve 
pacing for the right-sided treatments. Further freezes were delivered 
if the veins were not isolated. If this approach failed, the operator 
could take the alternative cryoballoon size or complete PV isolation 
using focal ablation. Focal lesions were applied with an 8 mm 
cryoablation catheter (Freezor Max, Medtronic, Minneapolis, MN, 
USA), and if this failed a 3.5 mm RF ablation catheter (Thermocool 
Celsius, Biosense Webster, Diamond Bar, CA, USA) was used.
   For RF, ablation energy was delivered using an irrigated F 
curve 3.5 mm non-contact force sensing ablation catheter (Navistar 
Thermocool, Biosense Webster, Diamond Bar, CA, USA) guided 
using CARTO 3 (Biosense Webster, Diamond Bar, CA, USA). 
Patients underwent WACA, with lesions placed 1–2 cm outside the 
PV ostia to isolate them in ipsilateral pairs. Power was limited to 
30W and flow was adjusted from 2 mL/min up to 30 mL/min to 
achieve this without exceeding temperature limit of 480C.
    For COMBINED, patients initially underwent WACA as 
in the RF group, with electrical isolation demonstrated using the 
circular mapping catheter followed by two further 5 min freezes 
using the cryoballoon, judged by good PV occlusion on venogram 
and temperatures of ≤ -400C.
   In all cases, electrical isolation of all PVs was the end point for 
the procedures.   
Follow-up
All antiarrhythmic drugs were stopped post procedure and patients 
were followed up at 3, 6 and 12 months with a 7 day Holter recording. 
There was open access to arrhythmia nurse specialists subsequently 
and further ambulatory monitoring prompted by symptoms. All 
patients with recurrence of symptoms and documented atrial 
arrhythmias lasting greater than 30s after the blanking period of 
3 months were offered a repeat procedure. Attempts were made to 
contact all the patients for review between 1 April to 31 May 2017 
to determine any adverse events, recurrences of AF/AT, current 
medications and symptoms. Patients with follow-up of less than 18 
months were excluded from analysis.
Study endpoints
    Success was defined as freedom from documented AF/AT 
lasting at least 30 seconds following a 3-month blanking period. The 
primary endpoint of the study was the success rate following a single 
procedure without antiarrhythmic drugs. Secondary endpoint was 
the success rate at last follow-up after one or more procedures off 
and on antiarrhythmic drugs.
PV reconnection sites at first repeat procedure
  All repeat procedures were performed with RF ablation using an 
open irrigated-tip catheter in conjunction with an electroanatomic 
mapping system. Using the multipolar circular mapping catheter, PV 
potentials were sequentially mapped and ablated until PV isolation. 
The positions of all reconnected PVs were prospectively documented.
 In a subset of patients during the first repeat procedure, the 
PV reconnection sites of each individual PV were prospectively 
documented. Each PV was categorized into eight individual 
segments as described by Valles et al[7] and was used to describe 
PV reconnection patterns. The site of the earliest PV potential was 
mapped and categorized into one of the eight segments. If antral 
ablation at that site eliminated all PV potentials, the respective PV 
Figure 1:
Comparison of AF free survival. Kaplan–Meier analysis of survival 
free from AF following (A) index procedure, (B) final repeat 
procedure(s) off anti-arrhythmic drugs, and (C) final repeat 
procedure(s) on anti- arrhythmic drugs for RF, CRYO and COMBINED 
groups. AF free survival at 5 years shown by dotted lines.
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Primary Endpoint: Freedom from AF/AT after a single 
procedure  
      Kaplan-Meier curves demonstrating freedom from AF/AT 
after a single procedure are shown in [Figure 1A]. At 5 years, 57% 
of COMBINED patients remained free of AF/AT after a single 
procedure compared to 47% CRYO and 19% RF patients (p<0.001 
COMBINED vs RF and CRYO vs RF; p=0.043 COMBINED vs 
CRYO). At final follow-up, 38/69 (55%) COMBINED patients 
remained free of AF/AT compared to 25/67 (37%) CRYO and 11/67 
(16%) RF patients. The COMBINED approach was superior to both 
was found to have a single conduction gap. If ablation resulted in a 
change in activation sequence, the earliest PV potential was mapped 
and ablated until complete PVI was achieved. Hence, more than one 
reconnection sites were possible per PV.
Statistical analysis
   Continuous data are presented as mean ± standard deviation 
if normally distributed or median ± inter quartile range if not. 
Categorical data are described as count (percentage). Continuous 
data were compared using Student’s t-test. Categorical data were 
Table 1: Patient characteristics















Age (years) 59±11 61±12 57±10 55±11 58±10 60±12 0.706
















LA diameter (mm) 43±5 43±5 43±4 42±5 43±4 42±4 0.736
Hypertension 2 (18%) 19 (34%) 12 (48%) 13 (31%) 10 (26%) 16 (52%) 0.506
DM 1 (9%) 4 (7%) 1 (4%) 3 (7%) 4 (11%) 1 (3%) 0.323
IHD 1 (9%) 5 (9%) 3 (12%) 3 (12%) 4 (11%) 1 (3%) 0.353
Cardiac failure 2 (18%) 2 (4%) 1 (8%) 6 (14%) 5 (14%) 3 (10%) 0.509
CVA/TIA 0 (0%) 6 (16%) 3 (12%) 2 (5%) 21 (11%) 5 (16%) 0.970
AADs failed 2±1 2±1 2±1 2±1 2±1 2±1 0.420
Patient characteristics in each group stratified by AF recurrence after a single procedure. Data shown as mean ± SD, median (IQR), or proportion (%) as appropriate. P-values shown are of univariate 
analysis assessing association of factors to recurrence of AF/AT.
compared using a chi-squared test and further pair-wise comparisons 
used Fisher’s exact test. Differences in survival on the Kaplan 
Meir curve was compared by log rank test. Univariate analysis was 
performed to assess for differences between groups and association 
of clinical characteristics with AF/AT recurrence. In all instances, 
a P value of <0.05 was considered statistically significant. Analysis 




Of the 234 patients in the original study, 203 patients (67 
RF, 67 CRYO and 69 COMBINED) had follow-up of at least 18 
months and were included in this analysis. The median follow-up 
duration was 5 years (IQR 3.6 to 6.4 years). [Table 1] compares the 
patient characteristics between the treatment groups, stratified by AF 
recurrence following a single procedure. There were no significant 
differences between the groups and no predictors of recurrence on 
univariate analysis.
RF (hazard ratio for AF recurrence, HR 0.33 95% CI 0.21-0.51) and 
CRYO (HR 0.63, 95%CI 0.39-0.99). CRYO in turn was superior to 
RF (HR 0.48, 95%CI 0.32-0.72).
Secondary Endpoint: Freedom from AF/AT after one or more 
procedures
   36/67 (54%) RF and 33/67 (49%) CRYO patients underwent 
one or more repeat procedure(s) compared to only 16/69 (23%) 
in the COMBINED group (p<0.01 for COMBINED vs RF and 
COMBINED vs CRYO) [Figure 2]. First repeat procedure was 
performed at median of 382 days (IQR 199-718 days) from index 
procedure with no significant differences between groups.
 After a mean of 1.7 procedures in the RF and CRYO groups, and 
1.3 procedures in the COMBINED group, 45/67 (67%) RF, 50/67 
(75%) CRYO and 54/69 (78%) COMBINED patients remained 
free of AF/AT off antiarrhythmic drugs (RF v COMBINED, 
p=0.02; RF v CRYO, p=0.10; CRYO v COMBINED, p=0.80). 
After repeat procedure(s) at a median of 5 years, the COMBINED 
group remained superior to RF (HR 0.48, 95%CI 0.25-0.92). There 
were no significant differences between COMBINED vs CRYO 
(HR 0.80, 95%CI 0.40-1.60) and CRYO vs RF (HR 0.60, 95% CI 
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OR 0.11 CI 0.03-0.48, p=0.002; COMBINED vs RF 0.16 CI 0.04-
0.63, p=0.008). The frequency of PV reconnection in the inferior 
veins was similar between the groups.
0.32-1.13) [Figure 1B].
 When patients who remain symptom free on antiarrhythmic 
medications are included, the efficacy after repeat procedure(s) rise 
to 65/67 (97%) for RF, 61/67 (91%) for CRYO and 66/69 (96%) for 
COMBINED (p=0.20 COMBINED vs RF; p=0.15 CRYO vs RF; 
p=0.75 COMBINED vs CRYO) [Figure 1C].
There were significantly more patients in the RF group on 
antiarrhythmic medications compared to patients in the CRYO and 
COMBINED group: RF 20/67 (30%) vs CRYO 9/67 (13%) and 
COMBINED 10/69(14%), p-0.04. There was 1 death in the RF 
group and 2 deaths each in the CRYO and COMBINED group. All 
deaths occurred more than 2 years after the index procedures.
Figure 2:
Number of AF ablation procedure(s). Number of AF ablation 
procedure(s) performed in each group.
Number and distribution of reconnected PVs during first 
repeat procedure
Among patients undergoing a first repeat procedure, 6/16 (38%) in 
the COMBINED group had no reconnected PVs compared to 2/33 
(6%) in the CRYO group and 2/36 (6%) in the RF group (CRYO/
RF versus COMBINED, p < 0.001). Patients in the COMBINED 
group also had fewer reconnected PVs (mean number of reconnected 
PVs in the COMBINED group 1.2 vs 2.3 CRYO and 2.4 RF, 
p=0.034). [Figure 3].
At the last procedure, 5/33 (15%) in the CRYO, 4/36 (11%) in the 
RF and 6/16 (38%) in the COMBINED group had no reconnected 
PVs.
Distribution of reconnected PVs and sites of PV reconnection 
during first repeat procedure
The distribution of reconnected PVs and sites of PV reconnections 
in each group is shown in [Figure 4].
There was a significant difference between the groups in the rate of 
reconnection among the superior veins between the groups. For RSPV, 
both CRYO and the COMBINED groups had significantly less 
reconnection compared to RF (CRYO vs RF, OR 0.28 CI 0.10 – 0.75, 
p=0.015; COMBINED vs RF, OR 0.13 CI 0.03-0.47, p=0.001). For 
LSPV, there was significantly less reconnection in the COMBINED 
group compared to both CRYO and RF (COMBINED vs CRYO, 
Figure 3:
Number of reconnected PV(s) during repeat procedure(s).Number 
of reconnected PV(s) documented during first and subsequent 
repeat procedure(s).
Figure 4:
Pattern of PV reconnection during first repeat procedure.
Distribution of PV reconnections during the first repeat procedure. 
Number in the centre circle of each vein represents the frequency 
of the vein being reconnected expressed as a percentage of the 
total number of patients in each group. Numbers in the periphery 
show the distribution of reconnection sites within each vein among 
the subset of patient for which this was prospectively evaluated. 
S- superior, A- anterior, I- inferior, P- posterior.
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years, AF free survival following cryoaballoon ablation drops to 47%.
There is limited long term (over 1 year of follow up) data for 
cryoballoon ablation in the literature. Vogt et al reported the 
outcomes of 605 patients who underwent cryoballoon ablation in a 
prospective registry [10]. Similar to our study, both 23 and 28mm Artic 
Front cryoballoons were used and Freezormax catheter was used 
when isolation was not achieved using the cryoballoon(s) alone. At 
1 year follow-up, AF free survival after a 3-month blanking period 
was around 70%. At median follow-up of 30 months, follow-up 
data were available for 451 patients with 62% remaining free of AF. 
One other observational study involving 139 patients reported 49% 
freedom from AF at mean follow-up of 457 days [11]. Our findings are 
consistent with these data.
Comparison of long term single procedure efficacy to RF and 
Combined approach
  The 1-year success rate obtained with conventional RF ablation 
was 47% and this dropped to 19% at median follow-up of 5 years. 
Recent multicenter trials and a large prospective registry have 
reported single-procedure success rates off antiarrhythmic drugs 
in the region of 43-50% at up to 2 years follow-up[2,12]. The results 
obtained with RF ablation in the current study therefore seem to 
be consistent with ‘real world’ practice. Cryoballoon ablation has a 
higher single-procedure AF free survival rate at 5 years, suggesting 
greater durability of PV isolation with this technology.
In contrast, AF-free survival for patients who had the combined 
approach was 57% during long-term follow-up. This suggests a lower 
rate of attrition compared to the other 2 groups and is comparable to 
other studies looking at rates of late recurrence[13].
We have previously suggested that the combined approach may be 
cost-effective over the long term by reducing the number of repeat 
procedures needed[14] but further study with appropriate economic 
modeling will be required to answer this question.
Patterns of PV reconnection comparing cryoballoon and RF 
ablation
We found a significantly different pattern of PV reconnection 
between the cryoballoon and RF group. Firstly, the RSPV appears 
to be less likely to be reconnected following cryoballoon ablation. 
Secondly, the anterior-inferior region appears more likely to be 
reconnected in patients undergoing cryoballoon ablation.
With the exception of Van Belle[11], other centers have also 
reported a lower incidence of PV reconnection of the RSPV 
following cryoballoon ablation with the left sided veins more likely 
to be reconnected than the right [4,15,16].
We are aware of only two studies which have characterized 
the pattern of PV reconnection sites within each vein following 
cryoballoon ablation. The first by Ghosh et al[17] studied 51 repeat 
procedures at a mean of 9 months following cryoballoon ablation. 
The study found that the anterior segments of the left-sided veins and 
the inferior segment of the RIPV was most likely to be reconnected.
PV reconnection sites were prospectively studied in a subset of 20 
consecutive cases each in the CRYO and RF groups, and 10 in the 
COMBINED groups. There were 72 reconnection sites in 51 PVs in 
the CRYO group, 80 reconnection sites in 58 PVs in the RF group, 
and 23 reconnection sites in 19 PVs in the COMBINED group.
For the CRYO group, the anterior-inferior region (anterior, 
anterior inferior and inferior segments) accounted for 43 out of 63 
sites (68%) where reconnection was found, compared to only 33 out 
of 81 sites (41%) in the same region in the RF group (P= 0.001). This 
pattern is most pronounced in the RSPV where 90% of reconnection 
occurred and least so in the LIPV where only 53% was accounted for.
For the RF group, the superior and inferior regions on the right 
sided veins (anterior superior, superior and posterior superior 
segments of the RSPV and anterior inferior, inferior and posterior 
inferior segments of the RIPV) were least likely to be reconnected, 
accounting for only 9 out of 45 (20%) of reconnected right sided 
PVs. For the left sided veins, there were no reconnection sites on the 
inferior segment of LSPV and superior segment of LIPV. The sites 
of reconnections were otherwise evenly distributed when assessing 
segments within one clock face of each other.
For the COMBINED group, the pattern of reconnection in the 
RSPV appears similar to the CRYO group with 5 out of 6 (83%) 
of PV reconnections occurring in the anterior-inferior region. 
Otherwise, the inferior veins were more likely to be reconnected, 




This study reports the 5-year outcome of three different PVI 
strategies for PAF: the cryoballoon, radiofrequency catheter ablation 
(RFCA) or a novel combined approach. We found that after a single 
procedure, the combined approach resulted in a significantly lower 
rate of AF recurrence in the long term compared to both cryoballoon 
and RFCA, and cryoballoon was in turn superior to RFCA. 
The combined approach was associated with significantly fewer 
reconnected PVs compared to the other two groups. The pattern of 
PV reconnection differed between those who underwent cryoballoon 
compared to those undergoing RFCA and may explain the synergistic 
effect of the combined approach. After repeat procedure(s), efficacy 
was similar between the groups with AF free survival of ~70-80% 
at 5 years off antiarrhythmic medications although the combined 
approach remained superior to RFCA. This combined with the 
proportion of patients with recurrence despite no PV reconnection 
suggest that even the perfect PVI strategy will have a long-term 
ceiling of ~80% success due to non-PV triggers.
Long term efficacy of the cryoballoon ablation
We have previously shown in a randomised controlled trial that 
the single procedure success rate off antiarrhythmic drugs at 1 year 
was 67% following ablation with the first generation cryoballoon[6], 
which was in keeping with other randomized studies and registry 
data[4,8,10]. The current study shows that at median follow-up of 5 
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equally affects all three groups of patients.
Contact force sensing technology is now available, as is the second 
generation cryoballoon with short to medium term outcomes 
comparing the two being reported [10]. It remains to be seen whether 
these advances or others will substantially impact long term success 
rates.
Although this study reports the outcomes of a previous generation 
technology, the results demonstrate that there appears to be a ceiling 
on long-term success with PVI alone strategy regardless of initial 
technique used and after repeated procedures.
Conclusion
We have shown that the 5-year outcome following a single 
catheter ablation procedure for PAF using a combined approach of 
RFCA followed by cryoballoon ablation is superior to that of either 
technique alone. Ablation with the cryoballoon was also superior to 
RFCA. The pattern of PV reconnection differs between cryoballoon 
and RFCA, which may explain the synergistic effect of the combined 
approach and low rates of PV reconnection at repeat procedures. 
These data suggest an excellent outcome at 5 years with an effective 
PVI strategy for PAF. However, the long-term success rate with such 
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